Designer small molecules to target calcium signalling

Joanna M. Swarbrick, Andrew M. Riley, Stephen J. Mills, Barry V. L. Potter

Research output: Contribution to journalArticlepeer-review

8 Citations (SciVal)


Synthetic compounds open up new avenues to interrogate and manipulate intracellular Ca<sup>2+</sup> signalling pathways. They may ultimately lead to drug-like analogues to intervene in disease. Recent advances in chemical biology tools available to probe Ca<sup>2+</sup> signalling are described, with a particular focus on those synthetic analogues from our group that have enhanced biological understanding or represent a step towards more drug-like molecules. Adenophostin (AdA) is the most potent known agonist at the inositol 1,4,5-trisphosphate receptor (IP<inf>3</inf>R) and synthetic analogues provide a binding model for receptor activation and channel opening. 2-O-Modified inositol 1,4,5-trisphosphate (IP<inf>3</inf>) derivatives that are partial agonists at the IP<inf>3</inf>R reveal key conformational changes of the receptor upon ligand binding. Biphenyl polyphosphates illustrate that simple non-inositol surrogates can be engineered to give prototype IP<inf>3</inf>R agonists or antagonists and act as templates for protein co-crystallization. Cyclic adenosine 5'-diphosphoribose (cADPR) can be selectively modified using total synthesis, generating chemically and biologically stable tools to investigate Ca<sup>2+</sup> release via the ryanodine receptor (RyR) and to interfere with cADPR synthesis and degradation. The first neutral analogues with a synthetic pyrophosphate bioisostere surprisingly retain the ability to release Ca<sup>2+</sup>, suggesting a new route to membrane-permeant tools. Adenosine 5'-diphosphoribose (ADPR) activates the Ca<sup>2+</sup>-, Na<sup>+</sup>- and K<sup>+</sup> -permeable transient receptor potential melastatin 2 (TRPM2) cation channel. Synthetic ADPR analogues provide the first structure-activity relationship (SAR) for this emerging messenger and the first functional antagonists. An analogue based on the nicotinic acid motif of nicotinic acid adenine dinucleotide phosphate (NAADP) antagonizes NAADP-mediated Ca<sup>2+</sup> release in vitro and is effective in vivo against induced heart arrhythmia and autoimmune disease, illustrating the therapeutic potential of targeted small molecules.

Original languageEnglish
Pages (from-to)417-425
Number of pages9
JournalBiochemical Society Transactions
Issue number3
Publication statusPublished - 1 Jun 2015


  • Adenophostin a
  • Calcium signalling
  • Chemical biology
  • Cyclic adenosine 5'-diphosphoribose (cADPR)
  • Myo-inositol 1,4,5-trisphosphate (IP<inf>3</inf>)
  • Nicotinic acid adenine dinucleotide phosphate (NAADP)


Dive into the research topics of 'Designer small molecules to target calcium signalling'. Together they form a unique fingerprint.

Cite this